Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double‐blind, 8‐week study
Yong Huo, Weimin Li, Randy L. Webb, et al.
Journal of Clinical Hypertension (2018) Vol. 21, Iss. 1, pp. 67-76
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study
Hiromi Rakugi, Kazuomi Kario, Masako Yamaguchi, et al.
Hypertension Research (2022) Vol. 45, Iss. 5, pp. 824-833
Open Access | Times Cited: 56
Twenty‐Four‐Hour Blood Pressure‐Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double‐Blind Multicenter Study
Kazuomi Kario, Hiromi Rakugi, Daisuke Yarimizu, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 8
Open Access | Times Cited: 17
Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment
Kōichi Yamamoto, Hiromi Rakugi
Hypertension Research (2021) Vol. 44, Iss. 10, pp. 1239-1250
Closed Access | Times Cited: 40
Angiotensin receptor–neprilysin inhibitors for hypertension—hemodynamic effects and relevance to hypertensive heart disease
Kazuomi Kario, Bryan Williams
Hypertension Research (2022) Vol. 45, Iss. 7, pp. 1097-1110
Closed Access | Times Cited: 22
Application of Angiotensin Receptor–Neprilysin Inhibitor in Chronic Kidney Disease Patients: Chinese Expert Consensus
Liangying Gan, Xiaoxi Lyu, Xiangdong Yang, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 21
Management of nocturnal hypertension: An expert consensus document from Chinese Hypertension League
Jing Liu, Yan Li, Xinjun Zhang, et al.
Journal of Clinical Hypertension (2023) Vol. 26, Iss. 1, pp. 71-83
Open Access | Times Cited: 12
The Impact of Different Antihypertensive Medications on Blood Pressure Variability in Hypertensive Patients and Clinical Application Progress
俊慧 李
Advances in Clinical Medicine (2025) Vol. 15, Iss. 01, pp. 565-572
Closed Access
Decoding the efficacy and safety profiles of anti-hypertensive agents by targeting RAAS: A systematic review and meta-analysis of clinical trials
Starry H. Rampengan, Derren David Christian Homenta Rampengan, Roy Novri Ramadhan, et al.
Electronic Journal of General Medicine (2025) Vol. 22, Iss. 3, pp. em645-em645
Closed Access
Asian Expert Consensus on Nocturnal Hypertension Management
Jing Liu, Yan Li, Kei Asayama, et al.
Hypertension (2025)
Closed Access
Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe
Donna Shu‐Han Lin, Tzung‐Dau Wang, Peera Buranakitjaroen, et al.
Journal of Clinical Hypertension (2020) Vol. 23, Iss. 3, pp. 556-567
Open Access | Times Cited: 27
The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
Su‐Kiat Chua, Wei-Ting Lai, Lung‐Ching Chen, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 13, pp. 2824-2824
Open Access | Times Cited: 22
Efficacy of angiotensin receptor blockers for nocturnal blood pressure reduction: a systematic review and meta-analysis
Jing Liu, Wei Chen, Shihuan Shao, et al.
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 3
Efficacy and Safety of Sacubitril/Valsartan in Chronic Type B Aortic Dissection Combined With Mild Hypertension
Xuelin Wang, Feier Song, Lujing Jiang, et al.
American Journal of Hypertension (2024) Vol. 37, Iss. 8, pp. 612-620
Closed Access | Times Cited: 2
Efficacy and Safety of Sacubitril/Allisartan for the Treatment of Primary Hypertension
Wei Zhang, Jin Zhang, Jie Yan, et al.
JACC Asia (2024) Vol. 4, Iss. 9, pp. 697-707
Open Access | Times Cited: 2
An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension
Markus Wehland, Ulf Simonsen, Niels Henrik Buus, et al.
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 10, pp. 1133-1143
Closed Access | Times Cited: 16
Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials
Yun Huang, YuYu Zhang, Lili Ma, et al.
Journal of Cardiovascular Pharmacology (2021) Vol. 78, Iss. 2, pp. 202-210
Closed Access | Times Cited: 14
Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation
Youzheng Dong, Zhenyu Zhai, Jihong Wang, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials
Ruxin Wang, Haowen Ye, Yongting Zhao, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 9
The Application of Angiotensin Receptor Neprilysin Inhibitor in Cardiovascular Diseases: A Bibliometric Review From 2000 to 2022
Xia Xu, Yumeng Li, Shuqing Shi, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 8
Effect of Sacubitril/Valsartan on Reducing the Risk of Arrhythmia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Ruxin Wang, Haowen Ye, Li Ma, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 8
Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials
Yake Lou, Ying Yu, Jinxing Liu, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 8
Efficacy and safety of sacubitril/allisartan for the treatment of primary hypertension: a phase 2 randomized, double-blind study
Jin Zhang, Wei Zhang, Jie Yan, et al.
Hypertension Research (2023) Vol. 46, Iss. 8, pp. 2024-2032
Closed Access | Times Cited: 4
Efficacy of angiotensin receptor neprilysin inhibitor in hypertension management: A systematic review and meta-analysis of clinical trials
Roy Novri Ramadhan, Derren David Christian Homenta Rampengan, Imke MDR. Puling, et al.
Narra J (2024) Vol. 4, Iss. 3, pp. e1247-e1247
Open Access | Times Cited: 1
Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysis
Gonçalo Martins e Pereira, Gonçalo S. Duarte, Vasyl Katerenchuk, et al.
Expert Opinion on Drug Safety (2021) Vol. 20, Iss. 5, pp. 577-588
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top